4Jackson G. A metabolic approach to the managent of ischemic heart di sease: cl inical benefits with trimetazidine [ J ]. Am J cardiovasc Drugs, 2003, 8 (suppl 1): 27-33.
4Boddeke E,Hugtenbung J,Jap W,et al.New anti-ischaemic drugs;Cytoprotective action with no primary haemodynamic effects.Trends Pharm Sci,1989,10:397～400.
5Deanfield JE.Therapeutic Value of a cardiprotective agent in patients with severe ischaemic cardiomyopathy.Eur Heari J,1990,11:207～12.
6Stanley Wc,Lopaschuk GD,Hall JL,et al.Regul-ation of myocardial cardohydrate metabolism under normal and ischae-mec conditions;potential pharmacological in tervention.Cardovasc Es,1997,33:243～57.
7Lavancy N,Martin J,Rossi A.Antl-ischaemiceffects of trimetazdine.31 p-NMR spectroscopy in the isolated rat heart.Arch Intern Phar-macodynther,1987,286:97～110.
2Fragsso G, Palloshi A, Puccett. P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure [J]. J Am Coll Cardiol,2006, 48:992 -998.
3Renee VC, Bertrand M, Xavier B. Beneficial effects of endurance training on cardiac and skeletal muscle energy metabolism in heart failure [J]. Cardiovascular Research, 2007, 73: 10-18.
6Reinert M,Andres RH, Fuhrer M,et al. Online correlation of spon- taneous arterial and intracranial pressure fluctuations in patients with diffuse severe head injury. Neurols ,2007,29(5 ) :455-462.
7Celermajel DS. Testing endothelial function using ultrasound. J Card- iovasepharmacol, 1998,32 ( suppl ) : S29-S32.
